Peel Hunt Reiterates “Buy” Rating for Circassia Pharmaceuticals (LON:CIR)

Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by Peel Hunt in a report released on Thursday, ThisIsMoney.Co.Uk reports.

Separately, FinnCap reiterated a “corporate” rating on shares of Circassia Pharmaceuticals in a report on Thursday, January 9th.

Shares of LON CIR opened at GBX 24.80 ($0.33) on Thursday. The stock has a market capitalization of $93.05 million and a P/E ratio of -0.74. The company has a 50-day moving average price of GBX 24.25 and a 200-day moving average price of GBX 19.88. Circassia Pharmaceuticals has a 1 year low of GBX 13.25 ($0.17) and a 1 year high of GBX 41.50 ($0.55). The company has a debt-to-equity ratio of 21.61, a current ratio of 0.40 and a quick ratio of 0.35.

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Further Reading: Which market index is the best?

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.